ArticleOncotarget2015

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

Mark Duquette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.